4 New Research Grants to Promote Study of Tumor Treating Fields as Cancer Therapy

4 New Research Grants to Promote Study of Tumor Treating Fields as Cancer Therapy
In a collaborative effort to support and advance innovative research on Tumor Treating Fields (TTFields) — a therapy that uses electric fields to promote cell death — the oncology company Novocure and the American Association for Cancer Research (AACR) will award four inaugural grants. A recent Phase 2 pilot clinical trial (NCT02244502) evaluated the therapy and showed that adding it to Taxol (paclitaxel) significantly slowed disease progression in recurrent ovarian cancer patients. Grant categories include the two-year, $250,000 AACR-Novocure Tumor Treating Fields Research Grant; the three-year, $225,000 AACR-Novocure Career Development Award For Tumor Treating Fields Research Grant; the two-year, $120,000 AACR-Novocure Tumor Treating Fields Research Fellowship, and the one-year, $25,000 AACR-Novocure Discovery Grant. The grant terms begin July 1. Proposals must emphasize preclinical applications of TTF in cancer, and may be basic or translational. Applicants must have a doctoral degree in a related field, and not currently be a candidate for a second doctoral degree. Investigators may concurrently apply for multiple AACR grants, but are expected to accept the first grant awarded. For eligibility questions, write to [email protected] Applications must be received by Feb. 8 by 1 p.m. (EST).  Grant recipients will be announced at AACR’s annual meeting, held this year from March 29 to April 3 in Atlanta. The awardees must attend. In a press release, Eilon Kirson, Novocure’s chief science officer and head of research and development, said the grant program seeks to provide a better understanding of how TTFields function, and to accelerate the development of new cancer treatments. “At Novocure, we are striving to extend survival in
Subscribe or to access all post and page content.